Jun 2026 (Q2 FY26) — Aug 3, 2026
GeneDx Q2 FY26 — Record Volume and Return to Profitability
Read the full callGeneDx (WGS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
GeneDx earnings: last reported Mon, 3 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 114 | +11.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -15.3 | −24.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -17.7 | −264.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$66.29 +4.21% · +$2.68
Performance −45.2% 1Y
1Y: $120.94 on 17 Oct 2025 → $66.29. High $167.52 (25 Nov 2025), low $34.51 (5 May 2026).
- Previous close
- $63.61
- 52-week range
- $34.51 – $167.52
- One year
- −47.82%
Overview
- Symbol
- WGS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
GeneDx earnings calls (WGS)
Financials
What the filings say
Net profit, year on year: −264% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 77 | 96 | 87 | 103 | 117 | 121 | 102 | 114 |
| Operating profit | -8 | 9 | -5 | 9 | -3 | -14 | -57 | -17 |
| Operating margin | −10.1% | 9.2% | −5.2% | 8.7% | −2.8% | −11.8% | −56.2% | −15.3% |
| Other income | -1 | -3 | -2 | 2 | -4 | -4 | -5 | -1 |
| Profit before tax | -8 | 5 | -6 | 11 | -7 | -18 | -62 | -18 |
| Tax rate | 0.6% | −0.4% | −7.3% | −2.3% | −3.3% | 3.1% | −1.4% | 2.8% |
| Net profit | -8 | 5 | -7 | 11 | -8 | -18 | -63 | -18 |
| EPS ($ per share) | -0.31 | — | -0.23 | 0.38 | -0.27 | — | -2.16 | -0.60 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | -330 | -575 | -1,124 | -1,300 | -1,352 | -1,373 |
| Total liabilities | — | 247 | 166 | 237 | 191 | 174 | 216 |
| Fixed assets | — | 63 | 63 | 52 | 32 | 33 | 46 |
| Investments | — | — | — | 0 | 30 | 56 | 66 |
| Total assets | — | 252 | 554 | 491 | 419 | 419 | 524 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -19 | -93 | -190 | -319 | -180 | -28 | 33 |
| Cash from investing | -15 | -32 | -21 | -141 | -44 | -30 | -62 |
| Cash from financing | 148 | 129 | 494 | 197 | 186 | 44 | 48 |
| Net cash flow | 114 | 4 | 283 | -263 | -38 | -14 | 20 |
| Capital expenditure | -12 | -24 | -9 | -7 | -5 | -5 | -19 |
| Free cash flow | -31 | -117 | -200 | -326 | -185 | -34 | 14 |
Insider filings
184 filings between Oct 29, 2025 and Sep 17, 2026.
Open market
decisions to buy or sellPurchases
$106.60M
34 purchases by 2 insiders
Sales
$21.81M
108 sales by 4 insiders
7% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 4
- Award — granted as compensation
- 38
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Meister Keith A. | $74.03M | — | May 15, 2026 |
| Casdin Capital, LLC | $32.57M | — | Jun 5, 2026 |
| Stueland Katherine | — | $11.51M | Sep 16, 2026 |
| RUCH JOSHUA | — | $6.09M | Nov 24, 2025 |
| Feeley Kevin | — | $3.36M | Sep 16, 2026 |
| Dechairo Bryan | — | $850.6K | Feb 4, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 17, 2026 | Fuchs Thomas Director | Option exercise | 1,146 | $0 |
| Sep 16, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 52 | $5.0K |
| Sep 16, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 1,470 | $144.5K |
| Sep 16, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Option exercise | 7,197 | $0 |
| Sep 16, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale | 148 | $14.1K |
| Sep 16, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale | 1,525 | $147.8K |
| Sep 16, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 1,079 | $106.8K |
| Sep 16, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 586 | $55.2K |
| Sep 16, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale | 4,141 | $406.9K |
| Sep 16, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 541 | $52.4K |
| Sep 16, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale | 1,648 | $155.3K |
| Sep 16, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale | 3,039 | $300.8K |
| Sep 16, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Option exercise | 18,750 | $0 |
| Sep 9, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Option exercise | 2,462 | $0 |
| Sep 9, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale | 3,692 | $310.9K |
| Sep 9, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Option exercise | 6,547 | $0 |
| Sep 9, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 1,285 | $108.2K |
| Sep 1, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 372 | $31.2K |
| Sep 1, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Option exercise | 717 | $0 |
| Jun 18, 2026 | Meister Keith A. Director | Option exercise | 3,576 | $0 |
| Jun 18, 2026 | PFENNIGER RICHARD C JR Director | Option exercise | 3,576 | $0 |
| Jun 18, 2026 | Leproust Emily M. Director | Option exercise | 3,576 | $0 |
| Jun 18, 2026 | Casdin Eli Director | Option exercise | 3,576 | $0 |
| Jun 18, 2026 | Ryan Jason Director | Option exercise | 3,576 | $0 |
| Jun 18, 2026 | RUCH JOSHUA Director | Option exercise | 3,576 | $0 |
| Jun 16, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Option exercise | 7,197 | $0 |
| Jun 16, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale | 2,429 | $149.4K |
| Jun 16, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale | 5,932 | $360.8K |
| Jun 16, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale | 2,140 | $127.9K |
| Jun 16, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Option exercise | 18,750 | $0 |
| Jun 16, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 863 | $53.1K |
| Jun 16, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 2,106 | $128.1K |
| Jun 16, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 760 | $45.4K |
| Jun 9, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 1,266 | $68.1K |
| Jun 9, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Option exercise | 2,462 | $0 |
| Jun 9, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Sale | 3,639 | $195.7K |
| Jun 9, 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER | Option exercise | 6,546 | $0 |
| Jun 5, 2026 | Casdin Capital, LLC Director | Purchase | 50,000 | $2.64M |
| Jun 4, 2026 | Casdin Capital, LLC Director | Purchase | 150,000 | $8.47M |
| Jun 1, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Option exercise | 717 | $0 |
| Jun 1, 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sale | 369 | $19.1K |
| May 20, 2026 | Casdin Capital, LLC Director | Purchase | 140,000 | $6.13M |
| May 19, 2026 | Casdin Capital, LLC Director | Purchase | 185,000 | $7.88M |
| May 18, 2026 | Casdin Capital, LLC Director | Purchase | 175,000 | $7.45M |
| May 15, 2026 | Meister Keith A. Director | Purchase | 18,865 | $751.4K |
| May 15, 2026 | Meister Keith A. Director | Purchase | 27,408 | $1.05M |
| May 14, 2026 | Meister Keith A. Director | Purchase | 88,107 | $3.44M |
| May 14, 2026 | Meister Keith A. Director | Purchase | 51,893 | $2.07M |
| May 13, 2026 | Meister Keith A. Director | Purchase | 70,926 | $2.80M |
| May 13, 2026 | Meister Keith A. Director | Purchase | 94,074 | $3.65M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for GeneDx Holdings Corp.
Free account. Everything above stays public.
Write why you follow GeneDx Holdings Corp. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading